Apr. 24 at 3:00 PM
$AKBA so Analysts’ 12-month price targets already take into account the current pipeline and the expected revenue trajectory from Vafseo, with an average target of around
$4. However, if the company receives approval to authorize up to 500 million additional shares and proceeds with issuing them (which seems very likely), that level of dilution would significantly impact valuation. In simple terms, the price target could effectively be cut in half to around
$2 to reflect the increased share count while maintaining the same overall company value. This also implies that, in a potential buyout scenario, even a
$2 billion valuation would translate into a much smaller ownership percentage for existing shareholders due to the expanded number of shares outstanding.
